Pathology and Lab Medicine: Recent Episodes
ReachMD
Guest: Fernando López-Ríos, MD, PhD
Guest: Christian Rolfo, MD, PhD
Guest: Charlie Gourley, MD, PhD
In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.
Topics of conversation include the following:
- An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
- Targeting HER2 in lung cancer: where does IHC testing fit in?
- Ovarian cancer: challenges and considerations for HER2 IHC testing
Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.
The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Host: Nathan A. Boggs, MD
Host: Tracy George, MD
Host: Lindsay Rein, MD
The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Guest: Donald Kohan, MD, PhD
Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City.
References:
- Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143
- Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023
- Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321
- Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301
- Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670
FA-11319389 12/24
Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease.
FA-11319389 12/24
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: William Grady, MD
While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.
Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Guest: Jyoti Patel, MD
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Host: Helena Yu, MD
Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.
Host: Jyoti Patel, MD
Guest: Pasi Antero Jänne, MD, PhD
Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.
Host: Benjamin Levy, MD
Guest: Alexander Spira, MD, PhD, FACP
Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Heather Wakelee, MD, FASCO
Guest: Lyudmila Bazhenova, MD
We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.
Guest: Jacob Sands, MD
Host: Charu Aggarwal, MD, MPH
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.
Host: Paul Paik, MD
Guest: D. Ross Camidge, MD, PhD
Guest: Keith Kerr, BSc, MB ChB
Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Sara A. Hurvitz, MD, FACP
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara A. Hurvitz, MD, FACP
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara M. Tolaney MD, MPH
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara A. Hurvitz, MD, FACP
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara M. Tolaney MD, MPH
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara M. Tolaney MD, MPH
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara A. Hurvitz, MD, FACP
Host: Sara M. Tolaney MD, MPH
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara M. Tolaney MD, MPH
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sara A. Hurvitz, MD, FACP
Host: Sara M. Tolaney MD, MPH
This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Erica L. Mayer, MD, MPH
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Erica L. Mayer, MD, MPH
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Erica L. Mayer, MD, MPH
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Erica L. Mayer, MD, MPH
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Erica L. Mayer, MD, MPH
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ disease but also in a new group of “HER2-low” patients. Clinicians will learn how to reframe their diagnostic and treatment paradigms, moving from a siloed view to a more nuanced assessment of breast cancer characteristics. Episodes will provide a greater understanding of how ADC targets and payloads, such as HER2 and Trop-2 can significantly improve a patient’s quality of life and extend their survival by increasing the pool of patients who may now benefit from ADCs. Aspects of diagnosing, treatment, and sequencing are discussed so that clinicians better understand how current and emerging ADCs address the unmet needs of patients with pretreated metastatic disease.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alex Herrera, MD
Guest: Alison J. Moskowitz, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Sarah Rutherford, MD
Guest: John P. Leonard, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Matthew J. Matasar, MD
Guest: Kami Maddocks, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: John P. Leonard, MD
Guest: Sarah Rutherford, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alex Herrera, MD
Guest: Alison J. Moskowitz, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alison J. Moskowitz, MD
Guest: Alex Herrera, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: John P. Leonard, MD
Guest: Sarah Rutherford, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Warner K. Huh, MD
Guest: Sarah E. Dilley, MD, MPH, FACOG
Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.
Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Host: Mark Socinski, MD
Guest: Kristin Higgins, MD
The clinical value of adding immunotherapy together with chemoradiation in locally advanced non-small cell lung cancer (NSCLC) has been evident since 2017. This concept has been extended through the emergence of key clinical trials, such as KEYNOTE-799, which includes both squamous and non-squamous subsets. In fact, the coalescence of chemoradiation and immunotherapy has begun to not only push up overall survival, but to also improve cure rates with manageable toxicity. But as the landscape rapidly changes, it becomes increasingly difficult to link evolving data to clinical practice. Join Drs. Mark Socinski and Kristin Higgins as they parse the key trials and offer insights that will help you provide better care, and possibly more hope, for your patients with locally advanced NSCLC.
Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Host: Fortunato Ciardiello, MD, PhD
Guest: Erika Martinelli, MD, PhD
Are you familiar with rechallenge strategies with anti-EGFR therapies to treat metastatic colorectal cancer? Listen as Drs. Fortunato Ciardiello and Erika Martinelli discuss patients most suitable for rechallenge with anti-EGFR therapies for metastatic colorectal cancer while outlining key clinical data.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient’s life.
Host: Barbara Burtness, MD
Guest: Nabil F. Saba, MD, FACP
KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remain in matching the correct patient with the correct strategy. Join Drs. Barbara Burtness and Nabil Saba as they parse the key trials and offer insight into building treatment algorithms designed to optimize outcomes for your patients with R/M HNSCC.
Host: Tanios S. Bekaii-Saab, MD
Guest: Joleen M. Hubbard, MD
Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Joleen Hubbard talk about the recent approval of tucatinib and trastuzumab for the treatment of HER2-positive metastatic CRC and other therapies in development.
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Petr Szturz, MD, PhD
While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.
Guest: Narjust Duma, MD
Guest: David J. Feller-Kopman, MD
Guest: Bruce E. Johnson, MD
Guest: Razelle Kurzrock, MD, FACP
Guest: Ignacio Wistuba, MD
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series.
PP-US-8201a-1520 12/22
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: William J. Gradishar, MD
Guest: Javier Cortes, MD, PhD
Guest: Hope S. Rugo, MD
New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you’re up to date and offering your patients the best care.
HPV testing plays an important role in cervical cancer screening, but not every patient whose HPV-positive will develop cervical cancer. One option that can help us identify which HPV-positive patients are truly at risk is CINtec PLUS Cytology, an immunohistochemistry test that simultaneously detects p16 and Ki67 biomarker proteins. Learn more about how this dual staining technique works in this video.
Host: Kevin J. Harrington, MBBS, PhD
Guest: Barbara Burtness, MD
Guest: Ari Rosenberg, MD
There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
Host: Richard S. Finn, MD
Guest: Peter R. Galle, MD
Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?
Host: Yelena Janjigian, MD
Guest: Sam Klempner, MD
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
Host: Benjamin Levy, MD
Guest: Rebecca Heist, MD, MPH
Guest: Peter Bela Illei, MD
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Jyoti D. Patel, MD, FASCO
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
Host: Paul Paik, MD
Guest: Catherine Shu, MD
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
Guest: Patrick Forde, MD
Guest: Jesús García-Foncillas, MD, PHD
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
Host: Janani Reisenauer, MD
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.
Host: Courtney DiNardo, MD
Guest: Marina Y. Konopleva, MD, PhD
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
Host: Guillermo Garcia-Manero, MD
Guest: Rami Komrokji, MD
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
Guest: Andrew M. Brunner, MD
Myelodysplastic syndrome (MDS) is a group of myeloid malignancies characterized by ineffective hematopoiesis, inflammation, and immune dysregulation in the setting of multiple genomic disruptions. Disease burdens associated with MDS encompass complications of the disease itself as well as those associated with transformation to acute myeloid leukemia (AML). Patients with high-risk MDS (HR-MDS) face even greater challenges, particularly when treated in community-based settings. This risk stems from the presence of greater numbers of cytogenetic abnormalities, which are unstable and associated with increased transformation to AML. Patients with HR-MDS and AML may not be candidates for allogeneic stem hematopoietic cell transplantation due to age or comorbidities. Hypomethylating agents (HMAs) remain as the standard of care for HR-MDS; however, responses to HMA do not exceed 50% and are short-lived. The efficacy of HMAs in some patients with MDS and their long-standing role in therapy have led to the development of novel treatment approaches that make use of HMA combination therapies with immune-based therapies, such as those that target the TIM-3 pathway.
This educational activity will focus on assessing MDS risk and its relation to treatment choices, the rationale and mechanism of action for novel immune-based therapies and integrating emerging combination therapies into clinical …
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Janani Reisenauer, MD
Guest: Colleen Channick, MD, FCCP, DAABIP
A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
Host: Mark Socinski, MD
Guest: Jennifer Marie Suga, MD, MPH
There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Andreas Rimner, MD
Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Eric Edell, MD, FCCP
Host: Septimiu Murgu, MD, FCCP
Guest: Narjust Duma, MD
Guest: Christopher Hartley, MD
Guest: Jeffrey Mueller, DO
Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.
Host: Luis Paz-Ares, MD, PhD
Guest: Kristen Marrone, MD
In the first-line management of non-small cell lung cancer, the use of immune checkpoint inhibitors (ICI) as monotherapy, as dual ICI, in combination with chemotherapy, or not at all is broadly dependent on which biomarkers are identified. While the choice of therapy is generally based on the level of expression of 1 or more biomarkers (eg, PD-L1, TMB), other factors often complicate this decision. Join us as Drs. Luis Paz-Ares and Kristen Marrone tackle these complexities by providing both foundational and clinical guidance to help you help your patients.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Anthony Mato, MD, MSCE
During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated.
This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …
Host: Heather Wakelee, MD, FASCO
Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC.
This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.
Host: Scott Kopetz, MD, PhD
Guest: Elena Elez, MD, PhD
Guest: Elizabeth Smyth, MD
Even with the recent advances in therapeutic options for patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC), they still have an uphill climb ahead of them.
How will the new standard of care in the second-line setting address global challenges and unmet needs regarding molecular profiling and treatment sequencing options?
Join us as 3 experts, Dr. Scott Kopetz, Dr. Elizabeth Smyth, and Dr. Elena Elez, untangle these new advances in treatment and offer their insights on how diagnostic testing can improve patient outcomes.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Maryam Lustberg, MD, MPH
Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.
Host: Jacob Sands, MD
Guest: Kathleen Fenn, MD
Guest: Oudai Hassan, MD
How do the 2018 ASCO/CAP guidelines redefine our approach to caring for patients with HER2-mutated breast cancer? Find out as Dr. Jacob Sands speaks with Dr. Kathleen Fenn and Dr. Oudai Hassan about HER2 scoring criteria and how the data drives collaborative care between the medical oncology and pathology teams.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Diane M. Harper, M.D., M.P.H., M.S.
While HPV 16 causes nearly 60 percent of the cervical cancers, it’s only associated with about 20 percent of the NILM, ASCUS, and LSIL cytology diagnoses. This means that 80 percent of early screening abnormalities associated with types other than 16 are missed. So how can we better detect types beyond HPV types 16 and 18? Joining Dr. Charles Turck to discuss same-genotype persistence for high-risk HPV is Dr. Diane Harper.
Host: Kristen Whitaker, MD, MS
Guest: Ricki Fairley, BA, MBA
Guest: Sara M. Tolaney, MD, MPH
For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.
This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.
Host: Miguel A. Escobar, MD
Guest: Cindy Leissinger, MD
Guest: Guy Young, MD
Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.
However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.
In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.
Guest: Pavani Chalasani MD, MPH
Has our understanding of HER2 status changed? Dr. Pavanai Chalsani from the University of Arizona Cancer Center dives into the reclassification of HER2 status and shares emerging clinical trial data.
Host: Mark Socinski, MD
Guest: Vivek Subbiah, MD
RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.
Host: Mark Socinski, MD
Guest: Benjamin Levy, MD
With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.
Host: Hyunseok “Hyu” Kang, MD, MPH
Guest: Jochen Lorch, MD
Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options.
This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.
Host: Mark Socinski, MD
Guest: Sandip Patel, MD
Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.
Host: Sara A. Hurvitz, MD, FACP
Guest: William J. Gradishar MD, FASCO, FACP
Guest: Nancy U. Lin, MD
HER2 is overexpressed and/or amplified in about 20% of breast cancers and signifies aggressive tumor behavior. New anti-HER2 therapies are improving the outlook for advanced or metastatic disease with targeted therapeutics, but while physicians now have a multitude of therapies to choose from, patient-specific characteristics and sequencing still present a challenge.
Tune in to enhance your knowledge and skills with this lively panel discussion examining 2 different patient cases with metastatic breast cancer (mBC). Explore optimal treatment selection based on patient-specific characteristics and ensure that you’re keeping up with the rapidly evolving landscape of HER2+ mBC. Find out what changes can make in your practice today to improve the lives of your patients.
Note that this program follows a previous case-based simulation activity titled “Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer.” This panel discussion analyzes choices made in that simulation and expands on optimal recommendations. If you haven’t participated in the simulation and would like to put yourself to the test, you can find the link to the activity in the related section.
Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about …
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Guest: Adam M. Brufsky, MD, PhD
Guest: Nina Thomas, MD
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
Host: Peter Libby, MD
Guest: Lawrence A. Leiter, MD
Guest: Prof. Kausik Ray, MBChB, MD, MPhil
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Daniel P. Petrylak, MD
Guest: Arlene O. Siefker-Radtke, MD
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Mark Socinski, MD
Guest: Justin Gainor, MD
With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you’re identifying everyone who can benefit from these newer therapies.
Host: Jacob Sands, MD
Guest: Tejas Patil, MD
What kind of role does next-generation sequencing play in HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Tejas Patil from the University of Colorado Medicine to explore the clinical utility of NGS and highlight opportunities to expand molecular testing into clinical practice.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
As the treatment landscape continues to evolve, what do we need to know about current treatment challenges and novel therapeutic options? Dr. Hector Chapa is joined by Dr. Sandra Misale to explore emerging therapies in HER2-mutated non-small cell lung cancer.
Guest: Nicolas Girard, MD
Guest: Alex Spira, MD, PhD, FACP
While the management and treatment of HER2-mutated non-small cell lung cancer continues to evolve, patients still face many unmet needs. Dr. Nicolas Girard, a pneumologist and Professor of Respiratory Medicine at Versailles Saint Quentin University, explores these unmet needs and how we can solve them.
Host: Misako Nagasaka, MD, PhD
One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC.
For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.
Host: Jacob Sands, MD
Guest: Howard (Jack) West, MD
Guest: Nicolas Girard, MD
How can we better diagnose and treat patients with HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Nicolas Girard and Dr. Jack West to explore diagnostic and therapeutic challenges and share collaborative patient management strategies for these patients.
Host: Jeffrey S. Weber, MD, PhD
Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.
In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.
Host: Scott Kopetz, MD, PhD
Guest: Rona Yaeger, MD
Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.
This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.
Guest: Edward B. Garon, MD
Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.
Guest: James G. Christensen, MD
Catch up on how new research presented at the 2021 ESMO Congress is helping to evolve targeted therapies for colorectal and pancreatic cancer with Dr. James G. Christensen.
Host: Johann de Bono, MD, PhD
Guest: Alicia K. Morgans, MD, MPH
Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.
This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.
The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Matt Birnholz, MD
Guest: Mark H. Stoler, MD
Now that vaccinated women have entered the screening population, we are seeing HPV 16 and 18 decreasing. These changes in HPV genotype prevalence may have a significant impact on the clinical management of cervical cancer, and an HPV test with extended genotyping may change the way we screen for cervical cancer as well. Joining Dr. Matt Birnholz to discuss the role of HPV extended genotyping in cervical cancer screening and the importance of identifying HPV 31 is Dr. Mark Stoler, Professor of Pathology and Clinical Gynecology at the University of Virginia Health System.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Guest: Maria E. Arcila, MD
Guest: Alexander Drilon, MD
Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.
The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.
This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
Guest: D. Ross Camidge, MD, PhD
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.)
Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on …
Host: Julien Taieb, MD, PhD
Guest: Scott Kopetz, MD, PhD
BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How will emerging regimens be utilized in daily clinical practice?
Join us as 2 experts, Dr. Scott Kopetz and Dr. Julien Taieb, examine strategies to enhance the personalized management of patients with BRAF V600E-mutated mCRC.
Host: Daniel Catenacci, MD
Guest: Yelena Janjigian, MD
Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.
Host: Richard T. Penson, MD, MRCP
Guest: Ana Oaknin, MD
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
Host: Richard T. Penson, MD, MRCP
Guest: Nicoletta Colombo, MD
Guest: Christine Ghione
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
Host: Robert Mocharnuk, MD
Guest: Johann de Bono, MD, PhD
Guest: Neeraj Agarwal, MD
During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.
PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.
In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a …
Host: Jacob Sands, MD
Guest: Lori Pierce, MD, FASTRO, FASCO
With only 3% of practicing oncologists identifying as Black, and less than 5% identifying as Latinx, how can we ensure these patient populations are equally represented in medical practice? Dr. Jacob Sands meets with ASCO’s current President, Dr. Lori Pierce, a Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs at the University of Michigan, to discuss ASCO’s plan to increase quality in cancer care and research.
Guest: Monica L. Baskin, PhD
Guest: Josep M. Llovet, MD, PhD
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC.
Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis.
In this activity, the expert faculty will review health disparities, inequities, and …
Host: Federico Cappuzzo
Guest: Professor Solange Peters
Guest: Professor Yi-Long Wu
Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.
Host: Peter Schmid, FRCP, MD, PhD
Guest: Javier Cortes, MD, PhD
Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lee P. Shulman, MD, FACMG, FACOG
Cervical cancer is the fourth most common cancer in women worldwide, which makes it essential for us to keep ahead of advances in cervical cancer prevention—advances like a biomarker-based cytology test. Here to discuss this and other recent advancements in cervical cancer screening is Dr. Lee Shulman, the Anna Ross Lapham Professor in Obstetrics and Gynecology in the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University.
Host: Jennifer Caudle, DO
Guest: Todd Askew
What’s being done to address the range of issues like the PPE shortage, lack of testing, and financial shortfalls encountered during the COVID-19 pandemic? Here to share his team’s advocacy efforts to help tackle these and other challenges is Todd Askew, the American Medical Association's Senior Vice President of Advocacy.
Guest: Mary Beth Pfeiffer
With cases being reported in every state and across 80 countries, Lyme disease has become one of the fastest growing vector-borne illnesses in the world. But have you ever wondered how this global health threat came to be? That’s what journalist Mary Beth Pfeiffer investigates in her book, Lyme: The First Epidemic of Climate Change, and with the ReachMD team.
Host: John J. Russell, MD
Guest: Meredith Wadman, BM, BCh, M.S.
Until the late 1960s, tens of thousands of American children suffered crippling birth defects if their mothers had been exposed to rubella, popularly known as German measles, while pregnant; there was no vaccine and little understanding of how the disease devastated fetuses.
In June 1962, a young biologist in Philadelphia, using human tissue samples sent from Sweden, produced a line of cells that allowed the creation of vaccines against rubella and other common childhood diseases. Two years later, in the midst of a massive German measles epidemic, the vaccine that would one day wipe out homegrown rubella was introduced. This vaccine has since protected more than 150 million people in the United States, and its development method has also led to other vaccines that have protected billions of people around the world from polio, rabies, chicken pox, measles, hepatitis A, shingles, and adenovirus.
Host Dr. John Russell chats with Meredith Wadman, author of The Vaccine Race: Science, Politics, and the Human Costs of Defeating Disease, about the story of both the science of this urgent race and the political and ethical controversies that nearly ended it prematurely.
Host: Matt Birnholz, MD
Guest: Robert McNally, MD
From the Villanova Health Summit's Speaker Event, host Dr. Matt Birnholz speaks with guest Dr. Robert McNally, President, and CEO of GeoVax, Inc. They discuss the challenges that biotech companies face when bringing vaccines through clinical trials, and the long-term project being conducted by his colleagues to deliver an HIV vaccine to market.
Host: Matt Birnholz, MD
Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide.
Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.
Host: John J. Russell, MD
Guest: David Fajgenbaum, MD
Castleman disease, a rare idiopathic multicentric disorder, is diagnosed in approximately 5000 people in the United States each year. When one 3rd year medical student suddenly found himself facing this diagnosis personally, at a time when knowledge about the disease was minimal, he helped create a broad-based initiative to address this knowledge gap.
Host Dr. John Russell talks with Dr. David Fajgenbaum, a Research Assistant Professor of Medicine in Translational Medicine/Human Genetics and Associate Director of Patient Impact for the Penn Orphan Disease Center at the University of Pennsylvania. He is also co-founder of the Castleman Disease Collaborative Network, a global initiative dedicated to accelerating research and treatment for Castleman disease and improving survival for all patients.
A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer’s disease Rosie Freer, Pietro Sormanni, Giulia Vecchi, Prajwal Ciryam, Christopher M. Dobson, and Michele Vendruscolo
Science Advances 10 Aug 2016: Vol. 2, no. 8, e1600947 DOI: 10.1126/sciadv.1600947
Abstract: In Alzheimer’s disease, aggregates of Aβ and tau in amyloid plaques and neurofibrillary tangles spread progressively across brain tissues following a characteristic pattern, implying a tissue-specific vulnerability to the disease. We report a transcriptional analysis of healthy brains and identify an expression signature that predicts—at ages well before the typical onset—the tissue-specific progression of the disease. We obtain this result by finding a quantitative correlation between the histopathological staging of the disease and the expression patterns of the proteins that coaggregate in amyloid plaques and neurofibrillary tangles, together with those of the protein homeostasis components that regulate Aβ and tau. Because this expression signature is evident in healthy brains, our analysis provides an explanatory link between a tissue-specific environmental risk of protein aggregation and a corresponding vulnerability to Alzheimer’s disease.
Laboratory safety may sound straightforward, but in reality it is supported by complex and ever-changing science. Safety standards and practices evolve as scientists learn more about the materials they handle regularly.
In this session of Public Health Grand Rounds from the CDC, presenters will discuss how standards of laboratory safety have improved over the years, what we’ve learned from past incidents, and how establishing safety protocols and training systems can lead to an overall culture of workplace safety, resulting in continued public trust in our science and recommendations.
For more details on this Grand Rounds session and its participants, click here.
Host: Harold Bays, MD, FNLA
Dr. Harold Bays welcomes Dr, Alan Remaley, clinical pathologist and Section Chief of the Lipoprotein Metabolism Section in the Cardiopulmonary Branch of the National Heart Lung, and Blood Institute in Bethesda, MD. Their discussion centers on LDL cholesterol from a variety of little-known aspects: its history as a biomarker for disease status, the ways in which it gets specifically measured, and the rise of lipid-altering pharmacotherapies to combat excessive LDL levels.
Host: Ana Maria Rosario
Pancreatic Cancer strikes fear into the hearts of every practicing internist, pathologist, oncologist, and general surgeon on behalf of their patients, and unfortunately for us all, it’s on the rise. By 2030 it will be expected to climb to the number-2 spot for causes of cancer death. What new insights can we bring to the recognition and identification of pancreatic cancer to help curb that trend? Joining host Ana Maria Rosario at Omnia Education’s Stages in Women’s Health in New York is Dr. Aimee Lucas, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York.
Host: Matt Birnholz, MD
National organizations such as the American Cancer Society and the American College of Obstetricians and Gynecology have published updated guidelines for cervical cancer screening. Crucial variations in these guidelines make implementing a sound, effective clinical protocol for management of gynecologic screening and treatment a challenge; and it is imperative that women's healthcare providers have a thorough understanding of clinical implications.
This Omnia Education program is presented by Dr. Thomas C. Wright, Jr., MD, Professor of Pathology at Columbia University College of Physicians and Surgeons.
Guest: Steven N. Austad, PhD
Host: Mary Leuchars, MD
The bowhead whale is the longest-living mammal on Earth. Its lifespan can exceed 200 years. What can we learn about fostering human longevity from the extraordinarily long-living animals in what author Dr. Steven Austad calls "Methuselah’s Zoo" (so named for Methuselah, the oldest figure in the Bible, said to have lived for 969 years)? Dr. Austad, professor of cellular and structural biology at the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center, talks to host Dr. Mary Leuchars.
Guest: Elizabeth Montgomery, MD
Host: Jay Goldstein, MD
Gastroenterologists and pathologists often rely on each other to care for patients. How can clinicians and pathologists best facilitate each other's work for the good of the patient? Dr. Elizabeth Montgomery, professor of pathology and oncology at Johns Hopkins University School of Medicine, explores the interaction between gastroenterologists and pathologists with host Dr. Jay Goldstein. Also, Dr. Montgomery outlines biopsy tips for gastroenterologists.
Guest: Michelle Mack, PA-C
Host: Lisa Dandrea Lenell, PA-C, MPAS, MBA
You've seen forensic investigators on TV detective shows like Law and Order and CSI but what is the job really like? Physician Assistant Michelle Mack, Director of Forensic Investigation at the Office of the Chief Medical Examiner in the District of Columbia, talks with host Lisa D'Andrea Lenell about how she puts together the puzzle surrounding a death investigation. The two also discuss how her PA training plays an integral role in her job and how she deals with the emotional side of a very difficult job.
Guest: Don Siegel, MD, PhD
Host: Lee Freedman, MD
What are cellular vaccines and how do they differ from what we think of as conventional vaccines? What are the various types of approaches that we can potentially use for inducing anti-cancer immunity? Dr. Don Siegel, vice chair and professor of pathology and laboratory medicine at Penn Medicine, talks with host Dr. Lee Freedman about the exciting potential of cellular vaccines as cancer therapy.
Guest: Robert Harman
Host: Bruce Japsen
Human stem cell treatments are only just emerging in clinical trials. but man's 'best friend' is already benefitting from pain relief and important treatments that are commercialized. And this work in dogs and cats could one day benefit human patients. Dr. Robert Harman, CEO and founder of Vet-Stem, tells the Chicago Tribune's Bruce Japsen about the latest efforts by a stem cell therapy developer to use fat cells for treatments, a therapy gaining momentum in pets and soon to be moving through clinical trials for humans.
Guest: Neal Goldstein, JD
Host: Larry Kaskel, MD
On October 30, 2008, the Centers for Medicare & Medicaid Services (CMS) published the 2009 Physician Fee Schedule, which includes revisions to the Stark regulations that tighten the prohibition on physician referrals and the anti-markup rules for diagnostic testing. Attorney Neal Goldstein explains that the changes made by CMS are an attempt to create a formulation that preserves the legitimate provision of in-office diagnostic services, while also cutting back on the proliferation of arrangements that have allowed physicians to profit from the diagnostic work of pathologists, radiologists and other specialists. Mr. Goldstein highlights the key tests for establishing compliance with the new anti-markup rules, though acknowledges that these revised regulations may unwittingly cause controversy within the pathology laboratory industry. Host Dr. Larry Kaskel explores the practical implications of these changes for the private and group physician practice.
Guest: Arlin Rogers, PhD
Host: Maurice Pickard, MD
Arlin Rogers, PhD, chief of comparative pathology at the Massachusetts Institute of Technology, details a new genome study which is helping to explain why men are saddled with liver cancer more often than their gender counterparts. Dr. Rogers aims to raise awareness for the influence of hepatitis B and C, and the role of an important cell mediator, in this disease trajectory. Find out more with host Dr. Maurice Pickard.
Guest: Randal Mills, PhD
Host: Bruce Japsen
2008 was a watershed year for stem cell-based treatment, with the first product of this kind going before an FDA review for approval. Learn more from Randal Mills, PhD, chief executive officer of Osiris Therapeutics, as he unveils details of his company’s stem cell-based medicine with host Bruce Japsen. How might the submission of this medicine for FDA approval start us down the path toward an array of stem cell products?
Guest: Randal Mills, PhD
Host: Bruce Japsen
While politicians debate whether there should be federal funding of embryonic stem cells, they might be over-looking a key point: the fact that all of the momentum in stem cell research is not in cells derived from human embryos at all. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about how all of the major clinical research in the U.S. is in adult stem cells.
Guest: Ophir Klein, MD, PhD
Host: Bruce Bloom, DDS, JD
Where do we stand with stem cell research, and what does the future hold for this controversial field of investigation? Host Dr. Bruce Bloom discusses stem cell research with Dr. Ophir Klein, of the Biomedical Sciences Graduate Program at the University of California, San Francisco.
Guest: Ophir Klein, MD, PhD
Host: Bruce Bloom, DDS, JD
What are the mechanisms behind animal tooth regeneration, and what can tooth stem cell research tell us? Your host, Dr. Bruce Bloom and Dr. Ophir Klein, of the Biomedical Sciences Graduate Program at the University of California, San Francisco discuss stem cell research and the potential clinical applications pointed to by the study of the mouse incisor.
Guest: Ophir Klein, MD, PhD
Host: Bruce Bloom, DDS, JD
Dr. Ophir Klein, of the Biomedical Sciences Graduate Program at the University of California, San Francisco discusses his research on the mouse incisor and its continual growth correlated with stem cells, with your host, Dr. Bruce Bloom. Listen in as the Dr. Klein explores the world of stem cell research on the mouse incisor as related to overall and specific organ development.
Guest: Jonathon Moreno, PhD
Host: Maurice Pickard, MD
Dr. Johnathan Moreno speaks with host Dr. Maurie Pickard about this year’s ground breaking research in the reprogramming of skin cells to act like stem cells. They also discuss the need for new embryonic cell lines that continue to be the gold standard. Continued progress in this area of research, however, is likely to be slowed due to the denial of federal funds, preventing the institution of guidelines of the National Institute of Health to facilitate the wide and rapid exchange of laboratory discoveries.
Guest: Douglas Losordo, MD
Host: Bruce Japsen
A journal Nature report that scientists cloned an embryo of a monkey and harvested its stem cells have grabbed headlines, but just how much progress are we really making in stem cell treatments? Dr. Douglas Losordo, head of the program in Cardiovascular Medicine at Northwestern University tells the Chicago Tribune's Bruce Japsen about progress in stem cell treatments.
Guest: John A. Kessler, MD
Host: Bruce Bloom, DDS, JD
John A. Kessler MD is Davee Professor of Stem Cell Biology and Chairman of the Davee Department of Neurology, Northwestern University Medical School. He discusses applying molecular neurobiology to clinical problems of spinal cord injury and stroke. Dr. Bruce Bloom hosts.
Guest: John A. Kessler, MD
Host: Bruce Bloom, DDS, JD
John A. Kessler MD, Davee Professor of Stem Cell Biology and Chairman of the Davee Department of Neurology at Northwestern University Medical School, is one of the world’s leaders in stem cell research to repair central and peripheral nerve damage. He joins us to talk about the biology of embryonic stem cells and neural stem cells, including the mechanisms regulating neuronal and glial differentiation.
Guest: Lee Philip Shulman, MD, FACOG, FACMG
Host: Lisa Mazzullo, MD
Few would quibble with the notion that every patient, irrespective of age, needs genetic screening. When it comes to prenatal testing, early answers are ideal for expectant mothers and their families. Dr. Lee Shulman, professor and chair of reproductive genetics at Northwestern University Feinberg School of Medicine, examines AFP-serum markers, triple and quad screens, and the increasing accuracy we’re now seeing among first trimester non-invasive testing.
Guest: Brian Kaplan, MD
Host: Lauren Streicher, MD
While freezing embryos has long been an option, many single women who hope to have a future partner, are requesting oocyte preservation rather than utilizing donor sperm. Dr. Kaplan discusses new methods of cryopreservation , current clinical recommendations and outcomes.
Guest: Sean Cutler, PhD
Host: Paul Raeburn
What can we learn about drug safety prior to human testing? How about using a plant considered "the lab rat of flora?" Turns out a lowly weedy mustard plant can tell us about about how people may react to drugs.
Guest: Clarisa Gracia, MD
Host: Lisa Mazzullo, MD
Dr. Gracia and Dr. Mazzullo discuss ovarian function and fertility before, during and after cancer treatments. The new ways in which we are beginning to perserve fertility provides hope for young cancer patients.
Guest: Clarisa Gracia, MD
Host: Lisa Mazzullo, MD
There are over 10 million new cancer diagnoses every year, and 5% occur in women of pre-pubescent and child-bearing ages. What impact does this have on their fertility, and what new measures are being taken before patients undergo treatment to protect the future of their fertility? Dr. Clarisa Gracia, assistant professor of obstetrics and gynecology at the University of Pennsylvania School of Medicine, joins host Dr. Lisa Mazzullo.
Guest: Nicholas Bergman, PhD
Host: Michael Benson, MD
In a scene from the recent Bruce Willis movie, Live Free or Die Hard, anthrax sensors were triggered, prompting evacuation of the FBI headquarters. Yet do such sensors really exist, or was this just another flight of Hollywood imagination? Our guest, Doctor Nicholas Bergman, reviews the nation's multi-faceted approach to defense against anthrax. Dr. Bergman received his PhD in biochemistry and molecular biology at the Massachusetts Institute of Technology. He is currently an Assistant Professor in the School of Biology at the Georgia Institute of Technology in Atlanta. He has published a paper examining some of the genomic properties of Anthrax in the Journal of Bacteriology.
Guest: John Brooks, MD
Host: Mark Nolan Hill, MD
In this segment Dr. John Brooks discusses a variety of pathology issues today. He talks about new equipment and technology, new immunohistochemical markers, errors in pathology, tissue samples and more.
Guest: John Brooks, MD
Host: Mark Nolan Hill, MD
Do pod labs violate the Stark Requirements? Are pod labs a case of physician self-referral? In this segment Dr. John Brooks talks about pod labs and other important issues facing pathologists today.
Guest: John Brooks, MD
Host: Mark Nolan Hill, MD
In this segment Dr. John Brooks explains the role of the pathology lab in the doctor/patient relationship.
Guest: John Brooks, MD
Host: Mark Nolan Hill, MD
Because sarcomas only account for a small percentage of new cancer cases, tissue samples for research purposes are not so easy to obtain. In this segment, learn from Dr. John Brooks how the LMS foundation started a tissue bank to help gather leiomyosarcoma tissue for research.
Guest: Jayanta Debnath, MD
Host: Bruce Bloom, DDS, JD
Autophagy and Anoikis sounds to the unfamiliar like a hip law firm, but in truth these terms describe cellular processes that may soon help us find the cure to cancer.
Guest: Jayanta Debnath, MD
Host: Bruce Bloom, DDS, JD
Autophagy-one of those words we remember from the basic science courses in med school-could it be relevant to curing cancer? Discussion on cancer research focusing on autophagy.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Guest: Elise Torczynski, MD
Host: Larry Kaskel, MD
Dr. Elise Torcynski will discuss the field of ohthalmic pathology, how she got into it, and how to make a living in such a highly specialized field. She will also share her insights on life threatening diseases of the eye and diseases that can be diagnosed through the eye.